EGRX — Eagle Pharmaceuticals Share Price
Last trade - 00:00- $22.08m
- $76.92m
- $316.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.36 | ||
| PEG Ratio (f) | 0.02 | ||
| EPS Growth (f) | 20.25% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.09 | ||
| Price to Tang. Book | 0.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | 1.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.32% | ||
| Return on Equity | 4.88% | ||
| Operating Margin | 13.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 213.31 | 195.89 | 187.8 | 171.55 | 316.61 | 258.29 | 224.81 | 5.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -29.81 | -63.04 | -14 | n/a | n/a | +20.25 | -25.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Directors
- Michael Graves NEC (58)
- Scott Tarriff PRE (61)
- Brian Cahill CFO (52)
- Michael Moran COO
- David Pernock EVP (66)
- Luciana Borio IND (50)
- Richard Edlin IND (60)
- Robert Glenning IND (60)
- Steven Ratoff IND (78)
- Jennifer Simpson IND (52)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- January 2nd, 2007
- Public Since
- February 12th, 2014
- No. of Shareholders
- 2
- No. of Employees
- 134
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 12,986,971
- Address
- 50 Tice Boulevard, Suite 315, WOODCLIFF LAKE, 07677
- Web
- https://www.eagleus.com/
- Phone
- +1 2013265300
- Auditors
- Ernst & Young LLP
Upcoming Events for EGRX
Similar to EGRX
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:20 UTC, shares in Eagle Pharmaceuticals are trading at $1.70. This share price information is delayed by 15 minutes.
Shares in Eagle Pharmaceuticals last closed at $1.70 and the price had moved by -59.91% over the past 365 days. In terms of relative price strength the Eagle Pharmaceuticals share price has underperformed the S&P500 Index by -62.54% over the past year.
The overall consensus recommendation for Eagle Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEagle Pharmaceuticals does not currently pay a dividend.
Eagle Pharmaceuticals does not currently pay a dividend.
Eagle Pharmaceuticals does not currently pay a dividend.
To buy shares in Eagle Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.70, shares in Eagle Pharmaceuticals had a market capitalisation of $22.08m.
Here are the trading details for Eagle Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EGRX
Based on an overall assessment of its quality, value and momentum Eagle Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eagle Pharmaceuticals is $17.00. That is 900% above the last closing price of $1.70.
Analysts covering Eagle Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $4.69 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eagle Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +193.29%.
As of the last closing price of $1.70, shares in Eagle Pharmaceuticals were trading -19.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eagle Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 0.36. The shares last closed at $1.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eagle Pharmaceuticals' management team is headed by:
- Michael Graves - NEC
- Scott Tarriff - PRE
- Brian Cahill - CFO
- Michael Moran - COO
- David Pernock - EVP
- Luciana Borio - IND
- Richard Edlin - IND
- Robert Glenning - IND
- Steven Ratoff - IND
- Jennifer Simpson - IND